logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Inc. (CNAT) Is Climbing On Phase 2 Study Results

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Wednesday that its Phase 2 clinical trial of emricasan showed that the drug reduced hepatic venous pressure gradient in patients with liver cirrhosis and severe portal hypertension. The stock is now up 1.89 on 1 million shares.

Conatus Pharmaceuticals rose during the first half hour of trade Wednesday, before settling into a range. Shares finished up by 0.78 at $5.74, with volume at a 6-month high. The stock surged to a 3-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>